Bingham Private Wealth LLC Acquires 4,827 Shares of Johnson & Johnson $JNJ

Bingham Private Wealth LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 123.7% during the 2nd quarter, Holdings Channel.com reports. The firm owned 8,728 shares of the company’s stock after purchasing an additional 4,827 shares during the period. Johnson & Johnson comprises 1.2% of Bingham Private Wealth LLC’s portfolio, making the stock its 18th largest holding. Bingham Private Wealth LLC’s holdings in Johnson & Johnson were worth $1,333,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the business. Apexium Financial LP boosted its holdings in Johnson & Johnson by 10.7% in the first quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock valued at $3,978,000 after acquiring an additional 2,310 shares during the last quarter. Avanza Fonder AB lifted its position in Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after purchasing an additional 6,566 shares during the period. Joel Isaacson & Co. LLC lifted its position in Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock valued at $12,294,000 after purchasing an additional 2,526 shares during the period. Tokio Marine Asset Management Co. Ltd. lifted its position in Johnson & Johnson by 7.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock valued at $12,164,000 after purchasing an additional 4,816 shares during the period. Finally, Absher Wealth Management LLC lifted its position in Johnson & Johnson by 1.2% during the 1st quarter. Absher Wealth Management LLC now owns 215,584 shares of the company’s stock valued at $35,752,000 after purchasing an additional 2,469 shares during the period. Institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on JNJ shares. UBS Group set a $198.00 target price on shares of Johnson & Johnson in a research report on Friday, October 3rd. Citigroup upped their target price on shares of Johnson & Johnson from $200.00 to $213.00 and gave the company a “buy” rating in a research report on Tuesday. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. The Goldman Sachs Group raised their target price on Johnson & Johnson from $185.00 to $186.00 and gave the stock a “buy” rating in a report on Friday, September 19th. Finally, Bank of America raised their target price on Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $189.88.

Johnson & Johnson Trading Up 0.5%

NYSE JNJ opened at $189.75 on Thursday. The firm has a market cap of $456.98 billion, a P/E ratio of 20.29, a P/E/G ratio of 2.41 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock’s 50-day moving average is $177.49 and its 200-day moving average is $163.37. Johnson & Johnson has a one year low of $140.68 and a one year high of $190.22.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.